secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2026-05-19T20:45:23+00:00
Accession:  0001437749-26-017799
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharmaceuticals secures U.S. commercialization rights to IMPAVIDO® for $4.25M fixed fees
--------------------------------------------------------------------------------

- Eton will pay $4.25M in fixed fees ($125k Jul 2026, then $1.25M Apr 2027, etc.) plus up to $4M in milestone payments based on cumulative net sales.
- Royalty rates: 55% of net sales up to $7M/year, 50% above $7M/year; Supplier covers product costs and regulatory, Eton covers sales and marketing.
- Exclusive U.S. commercialization rights start September 26, 2026; IMPAVIDO® had 2025 U.S. sales of $8.1M (Symphony Health).
- IMPAVIDO® is the first FDA-approved oral therapy for leishmaniasis (visceral, cutaneous, mucosal), a rare parasitic disease.
- This expands Eton's rare disease portfolio to eleven commercial products (including ten prior).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926017799/0001437749-26-017799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774926017799/eton20260518_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-017799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer